Phase 2 N=10 Indomethacin Versus Nifedipine for Preterm Labor Tocolysis
Obstetric Labor, Premature
Primary: Count of Patients With Recurrent Preterm Labor Within Two Weeks of Randomization — 2; 1 Participants — p=0.004
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=24 PERSEUS: Preliminary Efficacy and Safety of Cenicriviroc in Adult Participants With Primary Sclerosing Cholangitis
Primary Sclerosing Cholangitis
Primary: Percentage Change From Baseline Through Week 24 in Serum Alkaline Phosphatase (ALP) — -4.5 percentage change in ALP
Phase 2 N=11 Analgesic Effects of Topical Ketamine Mouthwash in Patients Receiving Chemoradiation or Radiotherapy for Head & Neck Cancer
Mucositis · Head and Neck Cancer
Primary: Change in Pain Score — 1.167; 1.58 score on a scale — p=0.3198
Phase 2 N=84 Study to Evaluate the Safety and Immunogenicity of 'IL-YANG Flu Vaccine Quadrivalent Inj' in Healthy Korean Adults
Influenza, Human
Primary: Seroconversion Rate — 58.93; 64.29; 64.29; 53.57 percentage of participants
Phase 2 N=72 Safety and Efficacy of BKM120 in Relapsed and Refractory NHL
Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
Primary: Overall Response Rate (ORR) and Disease Control Rate (DCR) Per Investigator at 6 Months (FAS) — 11.5; 22.7; 25.0; 30.8 percentage of participants
Phase 2 N=42 A Study of Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis
Psoriasis
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 13; 7; 20; 11 Participants
Phase 2 N=60 A First Time in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2798745 in Healthy Subjects and Stable Heart Failure Patients
Oedema, Pulmonary
Primary: Number of Participants With Vital Sign Values of Potential Clinical Concern in Healthy Participants — 0; 0; 8; 0 Participants
Phase 2 N=81 Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer
HER2-normal
Primary: Percentage of Participants With Feasibility — 70.4; 60.0 Percentage of participants — p=0.4422
Phase 2 N=25 Pharmacokinetics of 122-0551 and Its Effects on Adrenal Suppression
Plaque Psoriasis
Primary: Hypothalamic-Pituitary-Adrenal (HPA) Axis Response — 19; 6 Participants
Phase 2 N=137 Efficacy and Safety Study of Elagolix in Women With Endometriosis
Endometriosis, Pain
Primary: Change From Baseline in the Monthly Mean Dysmenorrhea Score During the Double-blind Treatment Phase — -0.24; -0.49; -0.37; -1.13 units on a scale — p=0.0262
Phase 2 N=64 PET/CT in Diagnosing Patients With Liver Cancer Undergoing Surgical Resection
Adult Hepatocellular Carcinoma · Localized Resectable Adult Liver Carcinoma
Primary: Fluorine-18 (18F) Fluoromethylcholine (FCH) PET/CT Parameters for Assessing Hepatocellular Carcinoma (HCC): Area Under the Receiver Operating Characteristic Curve…
Phase 2 N=17 Effect of Alendronate on Bone in People With Chronic Spinal Cord Injury (SCI) Previously Treated With Teriparatide
Spinal Cord Injury · Bone Loss · Osteoporosis
Primary: BMD of Total Hip by DXA — 1.32 Percent change
Phase 2 N=20 Trastuzumab, Cyclophosphamide, and Vaccine Therapy in Treating Patients With High-Risk or Metastatic Breast Cancer
Breast Cancer
Primary: Safety as Assessed by Number of Participants Experiencing Toxicity — 20; 0; 0 Participants
Phase 2 N=130 A Pivotal Study to Assess the Effectiveness of Nasal Dilator (Breathe Right Nasal Strips)
Congestion, Nasal
Primary: Change From Baseline in Mean Average Score of Nocturnal Rhinoconjunctivitis Quality of Life Questionnaire (NRQLQ) for Each Domain Problems (Sleep, Sleep Time, Symptoms…
Phase 2 N=25 12 Month Extension Study of the Effect of Teriparatide on Bone in People With Chronic Spinal Cord Injury (SCI)
Spinal Cord Injury · Bone Loss · Osteoporosis
Primary: Bone Mineral Density (BMD) of the Total Hip as Assessed by Dual-energy X-ray Absorptiometry (DXA) — 6.73; -0.34; 4.24 Percent change